ANNA MILSTEIN: Open Payments
NPI 1003914227 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,205 in 142 payments from 24 companies in 2025. Trend: 2023 $3,658 · 2024 $3,383 · 2025 $3,205
Food & beverage: $3,205
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 20 | $370 |
| Amgen Inc. | 16 | $294 |
| Novartis Pharmaceuticals Corporation | 12 | $292 |
| AstraZeneca Pharmaceuticals LP | 13 | $273 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $220 |
| PFIZER INC. | 6 | $193 |
| ABBVIE INC. | 8 | $188 |
| Radius Health, Inc. | 7 | $181 |
| Esperion Therapeutics, Inc. | 11 | $163 |
| Merck Sharp & Dohme LLC | 5 | $131 |
Products named: CAMZYOS, LEQVIO, Kerendia, EVENITY, NEXLETOL, VYNDAQEL, JARDIANCE, FARXIGA.
Industry payments across CA — which companies pay providers there.
